ACUT — ACCUSTEM SCIENCES Income Statement
0.000.00%
Last trade - 00:00- $6.66m
- $6.68m
Annual income statement for ACCUSTEM SCIENCES, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Total Revenue | 0 | 0 | 0 | 0 | 0 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Depreciation and Amortization | |||||
| Total Operating Expenses | 0.054 | 0.671 | 3.75 | 2.05 | 1.51 |
| Operating Profit | -0.054 | -0.671 | -3.75 | -2.05 | -1.51 |
| Net Income Before Taxes | -0.054 | -0.671 | -3.75 | -2.05 | -1.51 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | -0.054 | -0.671 | -3.75 | -2.05 | -1.51 |
| Net Income Before Extraordinary Items | |||||
| Net Income | -0.054 | -0.671 | -3.75 | -2.05 | -1.51 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -0.054 | -0.671 | -3.75 | -2.05 | -1.51 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -0.005 | -0.067 | -0.34 | -0.181 | -0.132 |
| Dividends per Share |